Skip to content
Screener

Shattuck Labs, Inc. STTK Other Research And Development — R&D

Other product segments

SL-325
$4.11M+57.7%
SL-846
$1.68M

Similar metrics at other companies

Nurix Therapeutics, Inc. logo
NRIXInternal research and development expenses — R&D
$56.56M+1.6%
BioMarin Pharmaceuticals logo
BMRNResearch and early pipeline — R&D
$85.07M-11.4%
Absci Corporation logo
ABSIExternal preclinical and clinical development — R&D
$6.85M+27.6%
Aquestive Therapeutics, Inc. logo
AQSTOther — R&D
$574K+16.4%
Insmed logo
INSMOther external R&D expenses — R&D
$48.84M+71.7%
Geron logo
GERNResearch and clinical expenses — R&D
$11.1M-43.9%

Other financials

Income statement

See full
Revenue-
Operating income-$16.2M-24.0%
Net income-$15.2M-21.6%
EPS (diluted)-$0.12+50.0%

Balance sheet

See full
Cash & equivalents$63.3M+25.4%
Total debt$2.7M-10.0%
Total equity$211.1M+270%
Total assets$220.7M+243%

Cash flow

See full
Operating cash flow-$10.2M+2.4%
CapEx$78.0K
Free cash flow-$10.3M+1.6%

Valuation

See full
Market cap$694.34M+1,826%
Enterprise value$633.72M-5,241%
P/S694.3×+682×

Profitability

See full
Operating margin-5,578.7%-15,316pp
Net margin-5,256.8%-14,625pp
FCF margin-4,124%-23,818pp

Returns & leverage

See full
Return on equity-39.2%-12.5pp
Debt / equity0.0×
Current ratio27.6×+17.3×

Where this comes from

Reported directly by Shattuck Labs, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Shattuck Labs, Inc.’s 10-Q, filed August 11, 2026.

Filed
Aug 11, 2026, 6:57 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-055483
RevenueThree Months Ended June 30, 2026 / $Three Months Ended June 30, 2026 / —Three Months Ended June 30, 2025 / $Three Months Ended June 30, 2025 / —
Research and development:
SL-32514,1072,604
SL-84611,679
Other research and development22,4792,878
Research and development non-equity compensation2,3602,331
Research and development equity compensation1,075867
Total research and development11,7008,680
General and administrative expenses:

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is Shattuck Labs, Inc.'s other research and development — R&D?
Shattuck Labs, Inc. (STTK) reported other research and development — R&D of $2.48M in Q2 2026.
How has Shattuck Labs, Inc.'s other research and development — R&D changed year-over-year?
Shattuck Labs, Inc.'s other research and development — R&D decreased by 13.9% year-over-year, from $2.88M to $2.48M.
What is the long-term trend for Shattuck Labs, Inc.'s other research and development — R&D?
Over 2 years (2023 to 2025), Shattuck Labs, Inc.'s other research and development — R&D has grown at a -25.5% compound annual growth rate (CAGR), from $22.34M to $12.4M.
What does other research and development — R&D mean?
This metric represents the total research and development expenditures specifically allocated to the 'Other' segment, which encompasses pipeline compounds and exploratory research activities outside of primary clinical programs. It reflects the company's investment in early-stage drug discovery and the maintenance of research infrastructure. Monitoring this figure helps investors assess the company's commitment to long-term pipeline diversification and innovation.

Ask your AI about Shattuck Labs, Inc.'s other research and development — r&d.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude